Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Would you consider therapy with AI plus CDK4/6i or AI alone in a patient with oligometastatic HR+ breast cancer with complete response to initial chemotherapy?
Related Questions
In metastatic hormone receptor positive breast cancer, would you consider combination exemestane and CDK4/6 inhibitor if letrozole and anastrazole are not tolerated?
How would you treat a patient with symptomatic and rapidly progressing metastatic HR+, HER2 low breast cancer with PIK3CA WT, ESR1 mutated, TMB high after progression on CDK 4/6 inhibitor, a taxane, and T-DXd?
Since the publication of DESTINY-Breast-04 have you implemented new institutional practices for characterization of HER2-low disease given known limitations in pathologist IHC evaluation?
Do you have a preference of denosumab over zoledronic acid in patients with metastatic breast cancer with osseous involvement with normal renal function?
Is Tucatinib as cardiotoxic as other anti HER2 agents?
Would you offer capivasertib+fulvestrant in a patient with metastatic HR+ HER2 negative breast cancer with PTEN mutation who has progressed on fulvestrant plus ribociclib?
Would you give T-DXd to patients with resolved drug-induced ILD from other agents such as prior chemo/targeted therapy/immunotherapy?
What is your approach in treatment of oligometastatic triple negative inflammatory breast cancer?
What strategies do you implement to control the nausea from Enhertu?
Is there a role for Elacestrant in ER+ metastatic breast cancer with ESR1-YAP1 fusion on NGS?
